Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oncogenes in melanoma.

David Polsky1, Carlos Cordon-Cardo

  • 1Department of Dermatology, New York University Medical Center, 550 First Avenue, New York, NY 10016, USA. David.Polsky@med.nyu.edu

Oncogene
|June 6, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SECmeres outperform extracellular vesicles as potential blood RNA biomarkers for Alzheimer's disease.

Nature communications·2026
Same author

Focal Small Bowel FDG Uptake in Cancer Patients Undergoing PET/CT: Prevalence and Etiology.

Clinical nuclear medicine·2026
Same author

Age-specific melanoma risk associated with nevi: a pooled analysis from the M-SKIP project.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

A Tumor-Promoting Inflammatory SPP1+ Macrophage-IL6-CRP Axis Drives Immune Dysfunction in Bladder Cancer.

Cancer discovery·2026
Same author

Author Correction: Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.

Nature genetics·2026
Same author

Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIV.

Vaccine·2025
Same journal

SRD5A3-mediated aberrant N-glycosylation of SCARA5 promotes ferroptosis in lung adenocarcinoma.

Oncogene·2026
Same journal

Aberrant splicing in human cancer shows possible functional impact on transcription factors.

Oncogene·2026
Same journal

The crosstalk between RNA m6A modification and protein lactylation: emerging insights into tumor progression.

Oncogene·2026
Same journal

Correction: Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.

Oncogene·2026
Same journal

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

Oncogene·2026
Same journal

Histone lactylation-driven IGF2BP3 promotes intrahepatic cholangiocarcinoma progression via SPP1/CD44-dependent macrophage polarization.

Oncogene·2026
See all related articles

Melanoma develops when growth pathways activate and tumor suppressors fail. Small molecule inhibitors targeting these growth pathways offer a promising new strategy for melanoma treatment, aiming to stop proliferation or trigger cell death.

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Melanoma development involves oncogene activation and tumor suppressor inactivation.
  • Growth-promoting pathways are typically activated, leading to uncontrolled cell proliferation.
  • Apoptotic and tumor suppressor pathways are inactivated, preventing normal cell death.

Purpose of the Study:

  • To provide an overview of oncogene activation mechanisms and functions.
  • To review oncogenic events specifically in melanoma.
  • To highlight the potential of small molecule inhibitors in melanoma treatment.

Main Methods:

  • Literature review of oncogene activation.
  • Analysis of oncogenic events in melanoma.
  • Overview of small molecule inhibitor research in oncology.

Related Experiment Videos

Main Results:

  • Oncogenes drive cellular proliferation by activating growth pathways.
  • Inactivation of tumor suppressor and apoptotic pathways contributes to melanoma.
  • Small molecule inhibitors targeting growth pathways are under investigation.

Conclusions:

  • Understanding oncogene activation is crucial for melanoma research.
  • Targeting growth stimulatory pathways with inhibitors presents a novel therapeutic approach.
  • Inhibitors may halt melanoma cell proliferation or induce apoptosis, offering new treatment options.